BR0209630A - Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais - Google Patents

Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais

Info

Publication number
BR0209630A
BR0209630A BR0209630-7A BR0209630A BR0209630A BR 0209630 A BR0209630 A BR 0209630A BR 0209630 A BR0209630 A BR 0209630A BR 0209630 A BR0209630 A BR 0209630A
Authority
BR
Brazil
Prior art keywords
cell death
chain protein
preventing cell
protein segments
tissue
Prior art date
Application number
BR0209630-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul A Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of BR0209630A publication Critical patent/BR0209630A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR0209630-7A 2001-05-16 2002-05-16 Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais BR0209630A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29097101P 2001-05-16 2001-05-16
PCT/CA2002/000712 WO2002092115A2 (en) 2001-05-16 2002-05-16 Method of preventing cell death using segments of neural thread proteins

Publications (1)

Publication Number Publication Date
BR0209630A true BR0209630A (pt) 2004-03-30

Family

ID=23118262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209630-7A BR0209630A (pt) 2001-05-16 2002-05-16 Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais

Country Status (12)

Country Link
US (1) US7572450B2 (enExample)
EP (1) EP1392347B1 (enExample)
JP (1) JP2004529179A (enExample)
KR (1) KR20040008177A (enExample)
CN (1) CN1558770A (enExample)
AT (2) ATE381342T1 (enExample)
BR (1) BR0209630A (enExample)
CA (1) CA2446945A1 (enExample)
DE (2) DE60205366T2 (enExample)
DK (1) DK1392347T3 (enExample)
ES (1) ES2247329T3 (enExample)
WO (1) WO2002092115A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259232B1 (en) * 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
BR0209990A (pt) * 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7544771B2 (en) * 2005-02-23 2009-06-09 Nymox Corporation Protein and its use in diagnosing Alzheimer's disease
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378924B1 (en) * 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
KR100392244B1 (ko) 1993-04-20 2003-11-28 더 제너럴 호스피탈 코포레이션 신경사단백질유전자발현및알쯔하이머병의검출
CN1300778A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白15和编码这种多肽的多核苷酸
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
US7259232B1 (en) * 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
DE60222745T2 (de) * 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren

Also Published As

Publication number Publication date
JP2004529179A (ja) 2004-09-24
DE60205366D1 (de) 2005-09-08
DE60205366T2 (de) 2006-05-24
DK1392347T3 (da) 2005-12-12
KR20040008177A (ko) 2004-01-28
ES2247329T3 (es) 2006-03-01
US20030004107A1 (en) 2003-01-02
CN1558770A (zh) 2004-12-29
CA2446945A1 (en) 2002-11-21
WO2002092115A3 (en) 2003-05-15
ATE381342T1 (de) 2008-01-15
ATE300951T1 (de) 2005-08-15
DE60224231D1 (de) 2008-01-31
EP1392347B1 (en) 2005-08-03
WO2002092115A2 (en) 2002-11-21
HK1060851A1 (en) 2004-08-27
US7572450B2 (en) 2009-08-11
EP1392347A2 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BR9903571A (pt) Método para inibição de glicogênio fosforilase humano
DE60143520D1 (de) Inhibitoren der histon-deacetylase
PT1297851E (pt) Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
DE69729007D1 (de) Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
MXPA04002397A (es) Inhibidores de histona deacetilasa.
BR9811099A (pt) Inibidores de urocinase
EP1582105A4 (en) METHOD FOR PREVENTING THE WATER CONTENT CHANGES OF A COMPOSITION AND ITS USE
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DK1392347T3 (da) Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
ATE229331T1 (de) Inhibitoren von metazoan-parasit-proteasen
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
BR0213126A (pt) Compostos heterocìclicos insaturados de 6 membros úteis para inibição seletiva da cascata de coagulação
MXPA01011924A (es) Metodos y composiciones para modular la respuesta inmunitaria y para el tratamiento de trastornos inflamatorios.
ATE239467T1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
ATE250030T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
EA200001140A1 (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
BR0009143A (pt) Mediação inflamatória obtida de atractylodeslancea
ES2144513T3 (es) Inhibicion de crecimiento tumoral inducido por traumatismo.
DK1121108T3 (da) Ny terapeutisk anvendelse af forbindelser med beta-3-agonistaktivitet

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.